Research & Development
ConTIPI Medical wins US FDA approval for marketing of unique product for treating pelvic organ prolapse in women
10 July 2019 -

Israeli biotechnology company ConTIPI Medical Ltd reported on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) to market itsthe first of its kind new product designed to treat pelvic prolapse in women (such as the uterus and bladder).

The CEO and founder Dr Elan Ziv, an expert in gynecology and urogynecology and Zeev Bronfeld, a biotechnology expert , have both invested in the company.

According to the company, the other investors include Boris Krasny, Capital Point Ltd and Neopharm Ltd.

To date, more than USD13m has reportedly been invested in ConTIPI Medical Ltd.



Related Headlines